07.09.15
Atlanta, Ga.-based CryoLife Inc., a medical device and tissue processing company focused on cardiac and vascular surgery, announced today that the Japanese Pharmaceuticals and Medical Device Agency (PMDA) has approved an expanded indication for Bioglue. Bioglue is now indicated for adhesion and support of hemostasis for aortotomy closure sites, suture/anastomosis sites (including aortic dissection and anastomosis sites with a use of a prosthetic graft), and suture sites on the heart. The product was previously approved for aortic dissection procedures in Japan, which is estimated to be a $5 million market. The expanded indication potentially doubles the estimated Bioglue market opportunity in Japan to more than $10 million.
CryoLife’s marketing partner in Japan, Century Medical Inc., is expected to begin selling Bioglue in the third quarter of 2015 for the expanded indications. BioGlue is the leading surgical adhesive used in cardiovascular surgery around the world and is used in a wide range of reconstruction procedures. To date Bioglue has been used in more than 1 million surgical procedures with more than 300 pre-clinical and clinical papers discussing its safety, efficacy, and application techniques.
“In conjunction with our distributor, Century Medical, we have already achieved meaningful commercial success with Bioglue in Japan,” said Pat Mackin, CryoLife chairman, president and CEO. “The expanded indication potentially doubles our market opportunity in Japan to over $10 million, allowing us to leverage our existing relationships to broaden the use of Bioglue into all aortic, cardiac, and large vessel procedures. We will work with Century Medical to train their team on the expanded indication, and we anticipate that they will be prepared to begin selling in the third quarter.”
CryoLife’s marketing partner in Japan, Century Medical Inc., is expected to begin selling Bioglue in the third quarter of 2015 for the expanded indications. BioGlue is the leading surgical adhesive used in cardiovascular surgery around the world and is used in a wide range of reconstruction procedures. To date Bioglue has been used in more than 1 million surgical procedures with more than 300 pre-clinical and clinical papers discussing its safety, efficacy, and application techniques.
“In conjunction with our distributor, Century Medical, we have already achieved meaningful commercial success with Bioglue in Japan,” said Pat Mackin, CryoLife chairman, president and CEO. “The expanded indication potentially doubles our market opportunity in Japan to over $10 million, allowing us to leverage our existing relationships to broaden the use of Bioglue into all aortic, cardiac, and large vessel procedures. We will work with Century Medical to train their team on the expanded indication, and we anticipate that they will be prepared to begin selling in the third quarter.”